VTX 806
Alternative Names: VTX-806Latest Information Update: 22 Nov 2024
Price :
$50 *
At a glance
- Originator Vivet Therapeutics
- Developer CIMA- Universidad de Navarra; Vivet Therapeutics
- Class Gene therapies
- Mechanism of Action CYP27A1 protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cerebrotendinous xanthomatosis